Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to buy a great stock on the cheap. The post At a bargain-basement valuation now, ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is undergoing a significant transformation in its therapeutic and competitive landscape. Accounting for approximately 75% ...

Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.

The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.